Oregon and Colorado Psilocybin Services Show Promising Real-World Mental Health Outcomes
A recent study by researchers at the University of Colorado Anschutz School of Medicine and Althea PBC has examined the real-world outcomes of psilocybin use in regulated service centers in Oregon and Colorado. The study, which analyzed data from 2,363 individuals over 15 months, found that participants experienced significant reductions in depression and anxiety scores. Specifically, 50% to 60% of participants showed at least a 50% reduction in their depression or anxiety scores two weeks after receiving psilocybin. The average dose administered was 29 mg, comparable to doses used in clinical trials. The findings suggest that the benefits observed in controlled clinical trials for psilocybin may also be apparent in real-world populations, despite less stringent screening procedures than those in clinical trials. Adverse events reported were generally mild and transient, such as nausea, anxiety, and headache, with no reports of novel psychosis. 
